ZA201103588B - Polypeptides,antibody variable domains & antagonists - Google Patents

Polypeptides,antibody variable domains & antagonists

Info

Publication number
ZA201103588B
ZA201103588B ZA2011/03588A ZA201103588A ZA201103588B ZA 201103588 B ZA201103588 B ZA 201103588B ZA 2011/03588 A ZA2011/03588 A ZA 2011/03588A ZA 201103588 A ZA201103588 A ZA 201103588A ZA 201103588 B ZA201103588 B ZA 201103588B
Authority
ZA
South Africa
Prior art keywords
antagonists
polypeptides
variable domains
antibody variable
antibody
Prior art date
Application number
ZA2011/03588A
Other languages
English (en)
Inventor
Ian Richard Catchpole
Gerald Wayne Gough
Michael Steward
Fiona Cook
Laurent Jespers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/323,632 external-priority patent/US20090148437A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA201103588B publication Critical patent/ZA201103588B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2011/03588A 2008-11-26 2011-05-16 Polypeptides,antibody variable domains & antagonists ZA201103588B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/323,632 US20090148437A1 (en) 2007-06-06 2008-11-26 Polypeptides, antibody variable domains & antagonists
PCT/EP2009/064654 WO2010060768A1 (en) 2008-11-26 2009-11-04 Polypeptides, antibody variable domains & antagonists

Publications (1)

Publication Number Publication Date
ZA201103588B true ZA201103588B (en) 2012-01-25

Family

ID=41507943

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/03588A ZA201103588B (en) 2008-11-26 2011-05-16 Polypeptides,antibody variable domains & antagonists

Country Status (11)

Country Link
EP (1) EP2356147A1 (zh)
JP (1) JP2012509852A (zh)
KR (1) KR20110091777A (zh)
CN (1) CN102224169A (zh)
AU (1) AU2009319175A1 (zh)
BR (1) BRPI0921319A2 (zh)
CA (1) CA2744055A1 (zh)
IL (1) IL212333A0 (zh)
MX (1) MX2011005540A (zh)
WO (1) WO2010060768A1 (zh)
ZA (1) ZA201103588B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2473528B1 (en) 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
EP3489258A1 (en) 2012-11-08 2019-05-29 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
EP3071181B1 (en) * 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
SG11201703574VA (en) 2014-11-07 2017-05-30 Eleven Biotherapeutics Inc Improved il-6 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
KR20080077261A (ko) * 2005-12-06 2008-08-21 도만티스 리미티드 Ｅｇｆｒ 및/또는 ｖｅｇｆ에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
JP2012509852A (ja) 2012-04-26
MX2011005540A (es) 2011-06-21
CA2744055A1 (en) 2010-06-03
CN102224169A (zh) 2011-10-19
IL212333A0 (en) 2011-06-30
BRPI0921319A2 (pt) 2018-10-16
AU2009319175A1 (en) 2010-06-03
KR20110091777A (ko) 2011-08-12
WO2010060768A1 (en) 2010-06-03
EP2356147A1 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
HK1138022A1 (zh) 多肽、抗體可變域及拮抗劑
IL214648A0 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
ZA200908454B (en) Polypeptides,antibody variable domains and antagonists
HRP20180873T1 (hr) Humanizirana anti-cxcr5 protutijela, njihovi derivati i njihova upotreba
EP2331579A4 (en) MONOCLONAL ANTIBODIES
HK1147269A1 (zh) 抗體
ZA201008993B (en) Anti-human interleukin-20 antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
GB0708002D0 (en) Antibodies
ZA201103588B (en) Polypeptides,antibody variable domains & antagonists
HK1136970A1 (zh) 五特異性抗體
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
IL236236A (en) Antibodies to the fam26f polypeptide
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
GB0811298D0 (en) Characterising polypeptides
IL218860A0 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
IL205073A0 (en) Anti-bst2 antibody
GB0718737D0 (en) Antibodies
IL203429A0 (en) Immunogenic polypeptides and monoclonal antibodies
EP2399934A4 (en) NEW MONOCLONAL ANTIBODY AND USE THEREOF
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
GB0718832D0 (en) Antibody fusions
GB0718834D0 (en) Antibody fusions